RxSight (RXST)
(Delayed Data from NSDQ)
$56.45 USD
+2.12 (3.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $56.47 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.45 USD
+2.12 (3.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $56.47 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Has Alcon (ALC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight
by Zacks Equity Research
Abcam, Integer Holdings and RxSight are part of the Zacks top Analyst Blog.
3 Medical Device Stocks With Potential to Fight Deflation Risk
by Indrajit Bandyopadhyay
Here we discuss three medical devices stocks, ABCM, ITGR and RXST, which have robust growth outlook in the long term. Betting on these stocks will help investors offset any potential deflationary risk.
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 14.89% and 8.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength?
by Zacks Equity Research
RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 19.23% and 7.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
RxSight, Inc. (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out.
4 Best Breakout Stocks to Buy Now for Superlative Returns
by Tirthankar Chakraborty
CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.
How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69%
by Zacks Equity Research
The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Does RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 42.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for RxSight, Inc. (RXST) points to a 45% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Q3 Earnings Lag Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of -8.33% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight, Inc. (RXST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
RxSight, Inc. (RXST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
RxSight, Inc. (RXST) delivered earnings and revenue surprises of 26.47% and 0.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?